Saamya Biotech (India) Limited reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2016. For the quarter, the company reported loss from operations from other income, interest and exceptional items was INR 2,525,490 against INR 2,643,124 a year ago. Loss from ordinary activities before and after tax was INR 2,525,331 against INR 2,644,391 a year ago. Net loss was INR 2,525,331 against INR 2,644,391 a year ago. Basic and diluted loss per share was INR 0.10 against INR of 0.11 a year ago. For the nine months, the company reported loss from operations from other income, interest and exceptional items was INR 8,220,831 against INR 7,791,389 a year ago. Loss from ordinary activities before and after tax was INR 8,226,939 against INR 6,835,065 a year ago. Net loss was INR 8,226,939 against INR 6,835,065 a year ago. Basic and diluted loss per share was INR 0.33 against INR of 0.27 a year ago.